Medical Device

ENDRA Life Sciences delivered and installed its next-generation Nexus 128+ preclinical imaging system at Kyungpook National University.

ENDRA Life Sciences (NASDAQ:NDRA) delivered and installed its next-generation Nexus 128+ preclinical imaging system at Kyungpook National University.
As quoted in the press release:

ENDRA’s preclinical photoacoustic CT scanners are used by leading global research scientists to study disease models. ENDRA’s proprietary hemispherical detector yields full volumetric 3D images of tissue in as little as 3 seconds, without compromised image quality that can result from commonly available slice-based 2D reconstructions. The Nexus 128+ provides up to twice the photoacoustic sensitivity versus ENDRA’s legacy Nexus 128, enabling improved quantitation of preclinical animal models.
“This is ENDRA’s second Nexus installation at a top research university in South Korea and we are excited about the growing global interest in ENDRA’s photoacoustic technology,” said Francois Michelon, ENDRA’s Chief Executive Officer. “Scientists at Kyungpook National University will be using ENDRA’s hemoglobin and probe uptake applications to conduct oncology research with the Nexus 128+ system.

Click here to read the full press release.

Source: www.accesswire.com

Featured

MARKETS

Markets
TSX20321.54+35.34
TSXV698.01-2.65
DOW31862.15-66.47
S&P 5003944.45+2.97
NASD11319.34+54.89
ASX7128.80-20.10

COMMODITIES

Commodities
Gold1844.92-22.36
Silver21.85-0.27
Copper4.26-0.05
Palladium1999.00+2.00
Platinum942.00-14.00
Oil110.00+0.23
Heating Oil3.70+0.05
Natural Gas9.12+0.33

DOWNLOAD FREE REPORTS

×